STOCK COMPARISON
Abbott Laboratories vs Stryker: Fair Value & Quality
Both stocks run through our valuation models. Here is how Abbott Laboratories (ABT) and Stryker (SYK) compare, as of Aug 8, 2026.
As of Aug 8, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Abbott Laboratories trades at $108 versus a fair value of $74.79 (-31%), while Stryker trades at $337 versus $186 (-45%).
Abbott Laboratories
ABT · USD · Health Care
-31%
upside to fair value
overvalued
Price$108
Fair Value$74.79
Quality64/100
Stryker
SYK · USD · Health Care
-45%
upside to fair value
overvalued
Price$337
Fair Value$186
Quality63/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Abbott LaboratoriesStryker
Valuation
27.7×P/E (TTM)36.0×
3.89×P/S (TTM)4.72×
3.36×P/B5.32×
15.1×EV/EBITDA18.8×
1.47×PEG1.58×
—Dividend yield1.0%
—Dividend per share$3.44
Profitability
14%Net margin13%
13%Operating margin18%
12%Return on equity15%
6%Return on assets8%
Growth
8%Revenue growth (YoY)3%
0.5%Avg. growth/yr (3Y)10.8%
5.1%Avg. growth/yr (5Y)11.8%
Balance & size
0.19×Debt / equity0.66×
$175BMarket cap$119B
healthyGrowth qualityhealthy
Abbott Laboratories leads: 8 to 5 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Abbott Laboratoriesof which business quality 66 · market factors 51
Strykerof which business quality 67 · market factors 49
ProfitabilityMargins and returns on capital today
50
52
Quality GrowthAre margins and returns improving?
47
61
CashflowEarnings quality: real cash, not paper profit
71
75
Fin. StrengthBalance sheet, leverage, solvency risk
80
68
InvestmentDisciplined investing over empire-building
65
66
Low VolatilityCalm price path (market factor)
83
76
MomentumPrice trend over the last 3–12 months (market factor)
40
39
52W MomentumDistance to the 52-week high (market factor)
34
35
Net IssuanceBuybacks instead of dilution
84
86
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Abbott Laboratories
DCF Models$70.99
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$69.29
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$64.43
26 of 26 models see the stock below the current price.
Stryker
DCF Models$188
Earnings-Based$95.43
Dividend Discount$58.93
Multiples$157
Asset-Based$39.18
Growth DCF$198
Economic Profit$84.35
Growth Earnings$152
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$108 = current price (white tick)
Stryker
Bear $112Fair Value $186Bull $233
$337 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Abbott Laboratories · Health Care
Quality score64 · Top 25%
Fair value upside-31% · below median
Stryker · Health Care
Quality score63 · Top 25%
Fair value upside-45% · below median
Bottom line
As of Aug 8, 2026, Fair Value Calculator sees Abbott Laboratories as the less overvalued of the two: Abbott Laboratories trades at $108 versus a fair value of $74.79 (-31%), while Stryker trades at $337 versus $186 (-45%).
Abbott Laboratories has the higher quality score (64/100).
See the full analysis →
More comparisons
Popular match-ups from the same sectors, all with fair value and quality score.
Free · Top-25 report
See the undervalued quality stocks every month
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
